Long-acting HIV treatment 'Vocabria+Rekambys' combination therapy aims to be listed for insurance reimbursement after receiving approval in South Korea two years ago.

Industry sources said that GSK Korea and Janssen Korea have applied for reimbursement for the combination therapy of Vocabria (cabotegravir) and Rekambys (rilpivirine), which each company owns. GSK will be responsible for the overall reimbursement process.

In February 2022, two drugs were approved by the Ministry of Food and Drug Safety (MFDS) as a combination therapy for the treatment of adult patients with HIV-1 infection who are virologically suppressed with no history of treatment failure and with no known or suspected